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1. Introduction 
1.1 Definition of infertility and habitual abortion 
Infertility is defined as an inability of a woman to carry a pregnancy to a viable foetus. From 
the perspective of differential diagnosis, infertility differs from sterility, i.e. an inability of a 
woman to get pregnant. If a woman miscarries on at least three consecutive occasions, this is 
termed habitual abortion (or habitual pregnancy loss, HPL). Habitual abortion is a stand-
alone nosological unit rather than an accumulation of circumstantial factors, as is confirmed 
by the lower incidence of foetal chromosomal aberrations in repeatedly miscarrying women 
compared to spontaneous abortions and a greater involvement of peristatic factors. A loss of 
all consecutive pregnancies in the first or second trimester is termed primary recurrent 
miscarriage. Secondary recurrent miscarriage is a situation when repeated miscarriages are 
preceded by a pregnancy leading to childbirth or an induced abortion. The term dysfertility 
is used if a woman miscarries on two consecutive occasions only (Zwinger, 2004). 
1.2 Epidemiology and etiology of habitual abortion 
Habitual abortion occurs in 1% of women in reproductive age and 15–38% of pregnancies 
result in spontaneous abortion. This number is, nevertheless, likely to be much higher as 
more than 40% of conceptions end before pregnancy is diagnosed (Madar, 2002). The 
frequency of spontaneous abortions increases with mother’s age. Up to 90% of the first 
spontaneous abortions result from, usually de novo, chromosomal aneuploidy, whereas the 
risk of recurrence of the same abnormality is minimal (Roztočil, 2001). Causes of habitual 
abortion include age, anatomy factors, genetic factors, haematology factors, endocrine 
factors, infections, immunology factors, environmental factors, psychological factors, 
idiopathic factors.  
1.3 Prerequisites of successful treatment of habitual abortion 
Successful therapy of infertile women is subject to a careful and individualised differential 
diagnosis of habitual abortions. Comprehensive evaluation aimed at identification of the 
specific cause of infertility should be performed in the pregnant women who have 
previously repeatedly lost their pregnancy. Rigorous approach to diagnose the causes of 
repeated miscarriage is essential when an effective therapy is to be selected. Causal therapy 
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of habitual pregnancy loss includes conservative pharmacological treatment, surgery and 
lifestyle changes. 
2. Endocrine causes of recurrent pregnancy losses 
An endocrinopathy is a common and severe cause of infertility. These are either 
gynaecology-related endocrinopathies and gynaecology-unrelated endocrinopathies. 
Gynaecology-related endocrinopathies results from ovarian hypofunction. Abnormal follicle 
stimulating/luteinizing hormone (FSH/LH) ratio and hyperandrogenism in the polycystic 
ovary syndrome are also considered as factors associated with an increased risk of habitual 
abortions. The proportion of first trimester miscarriages in women with the polycystic ovary 
syndrome is about 30–50% higher than in healthy women (Kauffman, 2003) 
Gynaecology-unrelated endocrinopathies with unequivocal impact on fertility include 
thyreotoxicosis, hypothyreosis, diabetes mellitus, hyperprolactinaemia and obesity 
(Krajčovičová, 2007).  
2.1 Gynaecology-related endocrinopathies 
Epidemiologically, polycystic ovary syndrome is a highly prevalent gynaecology-related 
endocrinopathy. However, it is not solely a gynaecological condition but rather a disease 
with a range of metabolic and endocrine findings, including diabetes (Moller, 1993, Toscano, 
1998). Ovarian hypofunction as a cause of habitual miscarriages represents another separate 
nosological unit of endocrinopathies with an impact on female reproductive function. 
2.1.1 Polycystic ovary syndrome 
It is estimated that polycystic ovary syndrome affects 5 – 10% of women of childbearing 
potential, with 35 – 45% of polycystic ovary syndrome patients being obese (Svačina, 2001). 
The real incidence of this syndrome in the population depends on the diagnostic criteria 
used and is probably higher than that published in the literature. Complications of 
pregnancy associated with maternal PCOS include increased prevalence of early pregnancy 
loss (EPL), gestational diabetes (GDM), pregnancy-induced hypertensive disorders 
(PET/PIH), and the birth of small-for-gestational-age (SGA) babies. Increased risk of EPL 
has been attributed to obesity, hyperinsulinaemia, elevated luteinizing hormone 
concentrations, and endometrial dysfunction. Avoiding obesity before pregnancy and 
treatment with metformin are therapeutic options, also for the increased prevalence of GDM 
(Homburg, 2006). Administration of metformin throughout pregnancy is a contentious 
issue. Screening pregnant women with PCOS for GDM and PET/PIH-especially if they are 
obese-is recommended, although data for a firm association between PCOS and PET/PIH is 
weak. Impaired insulin-mediated growth and foetal programming are possible explanations 
for a higher prevalence of SGA infants in mothers with PCOS (Homburg, 2006). 
2.1.1.1 Polycystic ovary syndrome - pathophysiology  
The mechanism behind metabolic and hormonal disposition for polycystic ovary syndrome, 
or what the primary disorder is, is rather unclear. Over the recent years, large groups of 
researchers have been involved in polycystic ovary syndrome research but the results are 
often controversial and confusing. Insulin resistance and the status of insulin receptors have 
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frequently been investigated. Page: 3 Higher insulin independent autophosphorylation of 
insulin receptor at serine residue was observed. The role of IRS substrate disorders is also 
discussed as is the role of TNF-a, e.g. IRS-1 phosphorylation induced by TNF-a (Svačina, 
2001). Defects of the glycoprotein PC-1 are being considered as another potential factor. 
Insulin resistance in male relatives has recently been shown. Phosphorylation of serine is a 
process that explains hyperanadrogenism as well as insulin resistance. This is a key process 
of androgen secretion in an ovary and adrenal glands and there also is important serine 
phosphorylation on insulin receptors (Svačina, 2001). 
A number of studies focused on the clear association with abdominal obesity (even though 
some of the patients are not particularly obese) and it seems that it is only the women with 
higher abdominal fat that are insulin resistant and hyperandrogenemic. SHBG reduction is 
typical, particularly in obese patients. Sex hormone-binding globulin (SHBG) is the primary 
plasma transport protein for sex steroid hormones and regulates the bioavailability of these 
hormones to target tissues. The gene encoding SHBG is complex and any of several 
polymorphisms in SHBG have been associated with alterations in circulating SHBG levels 
(Chen, 2010). Epidemiological studies have revealed that low plasma SHBG levels are an early 
indicator of insulin resistance and predict the development of type 2 diabetes mellitus (T2DM) 
in both men and women. Although association between low SHBG levels and risk of diabetes 
could be explained by the observation that elevations in insulin suppress hepatic SHBG 
production. Recent studies documenting that the SHBG-altering polymorphisms are 
associated with risk of T2DM suggest that SHBG may have a more direct physiologic role in 
glucose homeostasis (Chen, 2010). However, the exact mechanism(s) underlying this 
association is not known (Chen, 2010). Non-diabetic women with the polycystic ovary 
syndrome (PCOS), a common endocrine disorder that is associated with insulin resistance, 
similarly demonstrate lower levels of SHBG. In light of studies investigating polymorphisms 
in SHBG and T2DM, our group and others have hypothesized that SHBG may represent a 
candidate gene for PCOS. In this manuscript, we review studies investigating the association 
between SHBG polymorphisms and PCOS. In summary, multiple studies in women with 
PCOS confirm that certain genetic polymorphisms are associated with circulating SHBG levels, 
but they are not consistently associated with PCOS per se. (Chen, 2010) 
According to some authors, insulin resistance can be found in women with anovulation 
cycles only. Women with polycystic ovary syndrome have lower basal energy expenditure 
as well as postprandial termogenesis. This is an analogy with android obesity, metabolic 
syndrome and diabetes. A relative lack of gestagens and, consequently, dominance of 
cortisol on receptors in abdominal fat may also contribute to the pathogenesis. This results 
in higher level of free fatty acids and insulin resistance. 
To assess the diabetes risk score in polycystic ovary syndrome (PCOS) and in different 
phenotypes of PCOS and controls was observed and evaluated by overweight 
premenopausal women with PCOS, non PCOS or controls folowing factors: Finnish 
Diabetes Risk Score, anthropometrics, oral glucose tolerance test (OGTT), glucose, insulin, 
and reproductive hormone levels. The women with PCOS had higher adiposity, abdominal 
adiposity and 120-minute OGTT glucose. The women with PCOS and non-PCOS had 
elevated 120-minute OGTT insulin compared with controls. The women with PCOS and 
non-PCOS had similar diabetes risk scores, but both had higher diabetes risk score 
compared with controls after matching age and BMI. The women with PCOS (4%) and non-
PCOS (12%) had a lower prevalence of low risk of diabetes scores compared with controls 
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(50%) and they have similar Finnish Diabetes Risk Scores and elevated scores relative to 
controls independent of age and adiposity. Similar clinical screening and treatment practices 
for type 2 diabetes are warranted for both phenotypes of PCOS (Moran, 2011) 
Another research study compared pregnancy outcome, specifically the prevalence of 
gestational diabetes mellitus (GDM), in a group of patients with polycystic ovary syndrome 
(PCOS) to a group of healthy weight-matched women. Pregnancies of women with PCOS, 
who had been treated for infertility were compared with a group of age- and weight-
matched controls. There were no significant differences in the prevalence of pregnancy 
complications such as gestational diabetes mellitus, pregnancy-induced hypertension (PIH) 
and premature deliveries between the group of PCOS patients and the controls. When 
differences in age and weight between PCOS patients and controls are negligible, PCOS is 
not associated with a higher risk of pregnancy complications. (Hašková, 2003) 
2.1.1.2 Polycystic ovary syndrome - diagnosis  
The international conference in Bethesda in 1990 have recommended three diagnostic 
criteria: hyperandrogenism, chronic anovulation (enzyme deficits at a level of adrenal 
glands, e.g. 21-hydroxylase deficit as well as hyperprolactinaemia and androgen-producing 
tumours should be excluded) and hyperinsulinmia (Svačina, 2001). Frequent, although not 
exclusive, symptoms include hirsutism, alopecia and acne. There may be no morphological 
changes on the ovaries. An older definition assumed the presence of at least eight 
subcapsular cysts in the ovaries of 10 cm in diameter. Higher LH/FSH ratio (usually above 
2,0), previous important endocrine diagnostic criterion, is not anymore required for the 
diagnosis (Toscano, 1998). 
2.1.1.3 Polycystic ovary syndrome – treatment  
Management of polycystic ovary syndrome (PCOS) usually spans woman's reproductive 
years. While treatment of androgenic symptoms is often a primary concern, periodically, the 
regimen has to be modified because of a desire for pregnancy. At this time the couple should 
be evaluated for factors that may contribute to infertility and this should include semen 
analysis. However, for many, anovulation is likely to be the cause of infertility and ovulation 
induction is generally required. The premise on which ovulation induction in PCOS is based is 
two-fold: increasing ovarian exposure to follicle stimulating hormone (FSH) and/or correcting 
hormonal derangements. Potential differences in pathogenesis, evidenced clinically by 
phenotypic diversity, would suggest that treatment should be individualized. These options 
include the use of clomiphene citrate, insulin sensitizers, and the combination. Protocols for 
ovulation induction with FSH injections are outlined and the relative risks of multiple 
gestation and severe ovarian hyperstimulation syndrome. The use of aromatase inhibitors and 
the occasional use of glucocorticoids are briefly reviewed, and indications for in vitro 
fertilization and laparoscopic ovarian diathermy outlined (Nader, 2010). 
2.1.1.3.1 Clomiphene citrate and insulin sensitizers 
The knowledge on the role of insulin resistance in the pathogenesis of PCOS has led to the use 
of insulin sensitizers in PCOS treatment. Metformin was the first to be used in 1994. 
Administration of metformin results in decreased androgen and LH levels, improvement in 
insulin sensitivity and normalization of menstrual cycle (Legro, 2007). Metformin decreases 
liver gluconeogenesis and reduces oxidation of free fatty acids. It increases uptake of glucose 
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by skeletal muscles and fat tissue, improves dyslipidemia and it has other specific effects in the 
ovaries (Mansfield, 2003). Metformin impacts on ovarian steroidogenesis by reducing 
androgen production, improving the adverse environment of the endometrium and improves 
ovarian function. It seems so far that metformin (and glitazones) has no or insignificantly 
positive effect on hirsutism (Šarapatková, 2008). A meta-analysis of metformin studies showed 
that, compared to placebo, metformin significantly increases the occurrence of ovulation (Lord, 
2003). However, it is not clear yet whether treating women with PCOS and with normal BMI 
and insulin sensitivity with metformin is beneficial. Also, there is a question whether 
clomiphene should be used alone or in combination with metformin or whether metformin 
monotherapy should be used to enable infertile women with PCOS to become pregnant and 
deliver a healthy baby. In a 6-month study comparing all three approaches, clomiphene led to 
the highest pregnancy and live birth rates. Addition of metformin to therapy in this study did 
not show a significant advantage over clomiphene monotherapy. However, possible positive 
effect of this combination cannot be excluded. Induction of ovulation itself does not mean 
higher likelihood of conceiving and giving birth to a healthy child. Metformin provided, in line 
with previous findings, an improvement in parameters of insulin sensitivity, BMI, insulin and 
proinsulin levels, while insulin resistance and testosterone levels declined. Nevertheless, these 
effects may not be associated with higher rate of live births (Legro, 2007). 
Recently, glitazones, other insulin resistance modifying agents, have been tested in women 
with PCOS. They improve the effects of insulin in the liver, skeletal muscles and fat tissue. 
Similar to metformin, they also directly impact on ovarian steroidogenesis (Mansfield, 2003). 
Decrease in insulin levels results in decline in the levels of circulating androgens. Glitazones 
also reduce the levels of plasminogen activator inhibitor-1. Glitazones are not widely used 
in clinical practice and they are contraindicated in pregnancy (Šarapatková, 2008). The use 
of metformin in patients diagnosed with hyperinsulinaemia and in women with the 
polycystic ovary syndrome represents a therapeutic use of an insulin sensitizer with 
promising effects in anovulation sterility and dysfertility. 
2.1.1.3.2 Protocols for ovulation induction with FSH and in vitro fertilisation  
Women with PCOS and a history of habitual abortions or a history of sterility due to 
anovulation frequently undergo IVF cycles requiring ovarian stimulation with follicle-
stimulating hormone (FSH). In his retrospective study, Kdous compared standard long GnRH 
agonist protocol (Triptolerin) and GnRH antagonist regimens (Cetrorelix) in polycystic ovary 
syndrome (PCOS) patients undergoing controlled ovarian stimulation (COS) for ICSI cycles. 
He found that GnRH antagonist protocol is a short and simple protocol with a significant 
reduction in the incidence of OHSS and gonadotropin levels. However, GnRH antagonist 
protocol provides a lower live birth rate and an increased risk of early pregnancy loss 
compared to the GnRH agonist long protocol (Kdous 2009). Well-established 
micromanipulation techniques, the ICSI and PICSI methods, are successfully used for IVF in 
women with PCOS. Ovarian hyperstimulation syndrome (OHSS) is a feared complication of 
IVF. Women with PCOS are at a greater risk of developing OHSS because of the higher 
number of follicles produced in the ovaries following FSH stimulation (Moosová, 2011). 
2.1.1.3.3 Aromatase inhibitors  
Aromatase inhibitors block the final step in the enzymatic estrogen production: 
aromatization of the A-cycle of aromatizable androgens, specifically androstendione and 
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testosteron. Substances interfering with aromatase activity have been available for many 
years. However, the substances used during the aminoglutethimide era were non-specific 
and had a poor safety profile. The third generations of aromatase inhibitors are highly 
specific and virtually free of adverse events. These substances are licensed for treatment of 
breast cancer in postmenopausal women with advanced disease or as adjuvant treatment. 
Temporary inhibition of estradiol production in women with active ovaries leads to 
increased gonadotropin concentrations and, consequently, stimulation of follicle growth. 
This is undesirable in patients with ovarian cancer and thus aromatase inhibitors are not 
used in premenopausal women unless the production of gonadotropins is blocked. On the 
other hand, this effect is highly desirable in infertile women. Aromatase inhibitors may be 
used in women who do not ovulate but their no meaning (PCOS-type oligo-ovulation) or in 
ovulating women in whom higher number of follicles are required (idiopathic infertility, age 
factor, or prior to IVF). Preliminary studies published thus far show rather convincingly that 
aromatase inhibitors are effective in inducing ovulation in infertile women (Mitwally, 2006). 
Letrozole (one of aromatase inhibitors), though reported to be an effective ovulation 
inducing agent, warrants larger randomized trials. The purpose of this study is to compare 
the efficacy of letrozole with that of rFSH and clomiphene citrate (CC)/rFSH for ovarian 
stimulation in IUI cycles. In randomized, prospective, single-blinded clinical trial. 1387 
PCOS women after CC failure were randomized into three groups: Group A received 
letrozole, Group B received CC with two doses rFSH and Group C received continuous 
rFSH day 2 onwards until hCG injection. RESULTS: Group A, B and C had an ovulation rate 
of 79.30%, 56.95% and 89.89% and cycle cancellation rate of 20.70%, 43.05% and 10.11%, 
respectively. Pregnancy rates in Group A, B and C were 23.39%, 14.35% and 17.92%, while 
the miscarriage rates were 13.80%, 16.67% and 14.52%, respectively. CONCLUSION: 
Letrozole appears to be a suitable ovulation inducing agent in PCOS women with CC failure 
and is found to be most effective when baseline estradiol level >60 pg/ml. (Ganesh, 2009). 
2.1.1.3.4 Glucocorticoids  
In recurrently miscarrying women with PCOS, the presence of high titres of antizonal and 
antisperm antibodies should be excluded and potential insufficiency of sperm cell head’s 
enzymatic status considered. Patients in whom implantation is a problem, the presence of 
antizonal and antiendometrial antibodies has to be excluded. High levels of 
antiphospholipid antibodies and other mechanisms aimed at immunological mother-semi-
allogeneic graft tolerance might adversely affect the entire IVF process. Therapy is often 
carefully selected with respect to a patient’s age, character and type of antibodies and the 
number of IVF cycles. Most frequently, micromanipulation is combined with temporary 
immunosuppression (short-term administration of glucocorticoids, e.g. Prednison 5mg 
dosed 1-1/2-0 daily) and long-term antioxidant treatment (Ulčová-Gallová, 2001). 
2.1.1.3.5 Treatment by laparoscopic ovarian diathermy 
Laparoscopic ovarian drilling is used as one of the options for surgical management of 
infertility in patients with polycystic ovary syndrome. This method is performed as 
laparoscopic electrocautery with monopolar needle. Ovarian surface is systematically 
perforated with a needle and the surgery is frequently combined with a test of tubal patency 
or hysteroscopy as part of a comprehensive diagnostic laparoscopy. The effect of drilling on 
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reproductive function was evaluated by a number of studies. Kong compared the effects of 
laparoscopic ovarian drilling in treating infertile polycystic ovarian syndrome in patients 
with and without metabolic syndrome. A total of 89 infertile anovulatory polycystic ovarian 
syndrome patients, who underwent laparoscopic ovarian drilling with completed metabolic 
screening and seen over a 5-year period. The main outcome measures were clinical, 
hormonal and metabolic characteristics, as well as spontaneous ovulation rates, 
reproductive outcomes, and a risk of gestational diabetes after laparoscopic ovarian drilling. 
Approximately one fifth (21%) of polycystic ovary syndrome patients had metabolic 
syndrome. There were no differences in spontaneous ovulation rates (68% vs 61%, P=0.76), 
cumulative pregnancy rates (68% vs 61%, P=0.77), and a risk of gestational diabetes (64% vs 
42%, P=0.13) between patients with and without metabolic syndrome. Laparoscopic ovarian 
drilling was equally effective in inducing ovulation in polycystic ovary syndrome patients 
with metabolic syndrome. Thus, patients with metabolic syndrome should not be excluded 
from laparoscopic ovarian drilling, which has an additional advantage of enabling 
concurrent full tubo-peritoneal assessment (Kong, 2010). 
In randomized double-blind placebo-controlled pilot study Nasr evaluated N-acetyl-
cysteine (NAC) as an adjunctive therapy following unilateral laparoscopic ovarian drilling 
(LOD) for clomiphene citrate-resistant women with polycystic ovary syndrome (PCOS). 
Patients with clomiphene citrate-resistant PCOS who underwent unilateral LOD were 
assigned randomly to receive either NAC 1.2 g/d or placebo for 5 days starting at day 3 of 
the cycle for 12 consecutive cycles. The primary outcome was pregnancy rate; secondary 
outcomes were ovulation rates, endometrial thickness and pregnancy outcome. Baseline 
clinical, endocrine, and sonographic characteristics were similar in the two groups. A 
significant increase in both ovulation and pregnancy rates was observed in the NAC group, 
compared with placebo [87% versus 67% (RR 1.3; 95% CI 1.2-2.7) and 77% versus 57% (RR 
1.4; 95% CI 1.1-2.7), respectively, P<0.01]. Moreover, miscarriage rates were significantly 
lower and live birth rates were significantly higher in the NAC group [8.7% versus 23.5% 
(RR 0.4; 95% CI 0.1-3.7) and 67% versus 40% (RR 1.7; 95% CI 0.3-3.5), respectively, P<0.01]. 
NAC, a novel adjuvant therapy to be used following unilateral LOD, might improve overall 
reproductive outcome (Nasr, 2010). 
2.1.2 Ovarian hypofunction 
The main therapeutic aim of ovarian hypofunction management is to treat fertility disorders 
and to substitute the lacking hormones. Treatment of ovarian hypofunction-related 
dysfertility by assisted reproduction methods represents a complex issue. This group of 
patients (“low responders”) typically presents with low ovarian response to stimulation of 
foliculogenesis in in vitro fertilization cycles. 
2.1.2.1 Ovarian hypofunction – pathophysiology 
When discussing causes of recurrent miscarriages, experts differ in their opinion on the role 
of luteal insufficiency, the so called implantation factor. This is when a discrepancy occurs 
between adequate endometrial secretion and high nutritional needs of the fertilized egg, 
either during its free transport through the uterus before implantation or during 
histiotrophic nutrition. This discrepancy may lead to a suppression of embryonic 
development and the pregnancy ends in miscarriage in the first trimester (Erlebacher, 2004). 
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2.1.2.2 Ovarian hypofunction - diagnosis 
During a pre-conception assessment, luteal insufficiency should be considered in patients 
with very short secretory phase by basal temperature readings, recurrent severe retardation 
of secretory transformation of the endometrium by microabrasion, or a significant reduction 
in serum progesterone in the secretory phase of the menstrual cycle (Zwinger, 2004). 
2.1.2.3 Ovarian hypofunction - treatmen 
No optimal, universal and adequately effective IVF stimulation protocol can be found in the 
literature (Mardesic, 1995). In these stimulation cycles, higher doses of gonadotropic 
hormones are usually used and a lower number of oocytes are obtained. Whilst fertilization 
rate is within the norm, there is significantly lower percentage of obtained clinical 
pregnancies. With higher incidence of early pregnancy losses (mainly in women above 40 
years of age), the percentage of pregnancies ending in a delivery of a healthy foetus in 
women with reduced ovarian reserve is significantly lower than in dysfertile couples with 
other than ovarian factors of infertility. 
Stimulation protocols in this group of patients should use higher doses of rFSH (max. 300 
IU/D), in combination with GnRH antagonists (from 6th DC). Follicular phase of the cycle 
should not be prolonged because of the risk of premature ovulation and ovulation should be 
induced by an administration of 10 000 IU hCG when a minimum of 3 follicles ≥ 17mm are 
visible by UZ folliculometry. Oocytes should be withdrawn no later than 16th day of a 
menstrual cycle. Embryos obtained through prolonged cultivation and assisted hatching 
should be transferred under gestagen facilitation of luteal phase no longer than 20th DC. The 
most reliable and most successful method of achieving pregnancy in POF women is in vitro 
fertilization using a donated oocyte together with oestrogen-gestagen preparation of the 
endometrium (Hudeček, 2004). Stimulation of ovulation with gonadotropins in women with 
POF is ineffective. Centres of assisted reproduction report pregnancy rate in women with 
POF around 40 – 50% per cycle. Even though the child is genetically related to the father 
only, not to the mother, this method of infertility treatment in women with POF is generally 
acceptable, especially because the woman has a chance to carry the pregnancy to term 
herself and is able to breast feed the child (Žáková, 2006). There is about 5% chance in 
women who do not accept donated oocytes that they are able to get spontaneously pregnant 
despite the diagnosis of POF. The likelihood of this depends mainly on aetiology of POF 
(Altchek, 2003). 
There are discussions in the literature on utilization of native IVF cycles, protocols with 
minimum stimulation, including a possibility to convert a stimulation cycle into intrauterine 
insemination (Shahine, 2009, Schimberni, 2009). Even though these techniques of assisted 
reproduction show significantly lower efficacy, they may be considered as a treatment 
option in individual specific cases. 
A long-term hormonal therapy leading to pseudopregnancy followed by an administration 
of gestagens during a subsequent pregnancy (usually during the first trimester) is indicated 
in patients with luteal insufficiency. Decrease in estrogen receptors as progesterone receptor 
promoters can be modulated by the means of gestagen substitution (supra-physiological 
doses of progesterone – 150 mg per day) (Hudeček, 2004). 
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2.2 Gynaecology-unrelated endocrinopathies 
2.2.1 Thyrotoxicosis 
Thyrotoxicosis (hyperthyreosis) is a clinical syndrome caused by an overproduction of 
thyroid hormones. The main signs and symptoms of thyrotoxicosis result from 
hypermetabolism due to intensified oxidative processes in the body caused by excessive 
concentrations of these hormones. Graves-Basedow disease is the most frequent form of 
hyperthyreosis (60-85% of thyrotoxicoses) with a production of anti-thyroid peroxidase 
autoantibodies and anti-thyrotropin receptor antibodies. Approximately 10 – 30% of 
hyperthyreoses involve toxic multinodular goitre with autoimmune production of thyroid 
hormones (T3, T4). Inflammations also frequently cause hyperthyreosis by provoking T3 
and T4 secretion (Ďuriš, 2001). 
Clinical signs of thyrotoxicosis include nervousness, hand tremor, weight loss with 
increased appetite, palpitations, heat intolerance and hyperhidrosis. Other subjective 
symptoms include emotional lability, muscle weakness and diarrhoea. 
Objective symptoms include tachycardia or atrial fibrillation, high pulse pressure (the 
difference between systolic and diastolic pressure), precordial pulsation, and accentuated 
first sound above the apex of the heart. Gynaecological symptoms include polymenorrhoea, 
metrorrhagia, sometimes amenorrhoea or sterility. Warm, soft skin, goitre and increased 
psychomotor reactivity or restlessness may all contribute to the complete clinical picture of 
hyperthyreosis. 
2.2.1.1 Pathophysiology of thyrotoxicosis 
Hyperthyreosis might be accompanied by an increased level of gonadotropins, SHBG, 
estrogens and androgens (although the free fraction of these steroids is lowered due to the 
increased SHBG levels). A change to the concentration of free steroids and direct effect of 
thyroid hormones frequently causes anovulation and luteal insufficiency. Hyperthyreosis 
might be associated with polymenorrhoea and metrorrhagia as well as amenorrhoea and 
sterility. Some studies have shown that the autoimmune thyroiditis (AT) itself, without 
obvious or subclinical thyroid gland dysfunction, diagnosed before conception, is associated 
with infertility, recurring miscarriages and more frequent failure of assisted reproduction 
methods (Stagnaro-Green , 2004, Poppe 2003). 
One theory uses immunological mechanisms to explain the association between infertility 
and AT without thyroid gland dysfunction (Poppe, 2003). Some published papers identified 
concurrent occurrence of anti-thyroid and anti-ovarian antibodies; this may contribute to 
explain the association between AT and ovarian dysfunction (Sterlz, 1997). However, cell 
immunity is more likely to be responsible for recurring miscarriages. According to this 
theory, AT is one of the symptoms of a systemic autoimmune disease and represents an 
indicator of an alteration of the woman’s immune system responsible for recurring 
miscarriages. Elevated levels of CD 5/20 lymphocytes identified in women with AT and an 
increased risk of miscarriage supports this theory (Roberts, 1996). 
2.2.1.2 Diagnosis of thyrotoxicosis  
Thyrotoxicosis is diagnosed from the patient’s medical history and an assessment of the 
clinical picture and laboratory parameters. Thyrotoxicosis is characterised by decreased and 
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even undetectable TSH level and hyperthyroxinemia. TSH levels above 0.1 mU/L exclude a 
significant form of thyrotoxicosis. An optimal way of treatment should be decided from 
serum autoantibody levels (anti-thyroid peroxidase autoantibodies, anti-thyrotropin 
receptor antibodies). Imaging methods and gammagraphy of the thyroid gland are also 
important (Ďuriš, 2001). 
2.2.1.3 Treatment of thyrotoxicosis 
Treatment of hyperthyreosis includes lifestyle changes (regular, substantial food intake, 
avoiding extreme temperatures and excessive physical activity), thyreostatic treatment, 
subtotal strumectomy and treatment with radioiodine. Pharmacological thyreostatic 
treatment suppresses the overproduction of thyroid hormones by the thyroid gland. The 
thiouracil derivatives and carbimazole represent the first line treatment. A surgical 
treatment, subtotal strumectomy, can be applied when remission was achieved using a 
thyrostatic agent (florid thyrotoxicosis is a contraindication to any surgery as the patient is 
at risk of developing thyrotoxic crisis). An administration of a therapeutic dose of 
radioiodine is indicated when thyrotoxicosis is a co-morbidity to cardiopathy and when 
thyrotoxicosis recurred following strumectomy (Ďuriš, 2001). 
2.2.2 Hypothyreosis 
Hypothyreosis is a disorder characterized by decreased thyroid hormone levels. The 
prevalence of hypothyreosis in the population is about 5-8%, higher in women than men 
(8:1) and increases with age. Hypothyreosis should always be thought of in older women 
(prevalence 15 – 20%), not only if the patient presents with specific symptoms but also if 
they report general complaints such as fatigue, depression and myalgia. Autoimmune 
thyroid gland disease as well as, understandably, post-thyroidectomy states or treatment 
with radioiodine are among the most frequent causes. The clinical picture is diverse and 
includes fatigue, inefficiency, somnolence, depression, poor cold tolerance, weight gain, 
feeling of pressure on the neck (may also occur if the thyroid gland is not enlarged during 
AIT), dry skin, myalgia and arthralgia. 
The thyroid gland may be enlarged, nodular as well as reduced, thinking and motor 
functions are slowed down, hypomimia, oedema of the face, eye lid oedema, macroglosy, 
deep voice. Anaemia is usually normochromic, pernicious in about 10% of cases and 
associated with autoimmunity, gynaecological symptoms include menstrual cycle disorders, 
menorrhagia, infertility and galactorrhoea (Brunová, 2008). 
2.2.2.1 Pathophysiology of hypothyreosis 
Hypothyreosis is one of the most important endocrine primarily non-gyneacological 
endocrinopaties that affect female fertility. Untreated hypothyreosis reduces fertility, 
increases the incidence of spontaneous abortions and increases the incidence of premature 
deliveries (Ďuriš, 2001). Manifest hypothyreosis is frequently linked to anovulation, 
oligomenorrhoea or amenorrhoea and infertility. Thyroid hormones directly impact on the 
correct function of oocytes, lutein cells and granulosa cells. In addition, hypothyreosis is 
associated with a reduction of gonadotropins (particularly the luteinizing hormone) and 
with an increase in prolactin levels; this results in a decreased production of ovarian 
steroids. Reduced levels of thyroid hormones result in their reduced production and, 
consequently, the sex hormone binding globulin (SHBG) levels also decline, the level of free 
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testosterone increases as does peripheral aromatization of androstendione to estrone 
(Krassas, 2000). Thyroid hormones are very important for intrauterine foetal development, 
particularly for the development of the brain and for the development of the hypothalamic-
pituitary-thyroid axis. Gravidity represents a period when an increased production of 
thyroid hormones is required. The foetus depends completely on the mother during the first 
trimester, and the contribution of the mother to foetal hormonal levels remains significant 
throughout (maternal productions after birth represent about 30% of thyroxin in the 
umbilical cord blood) and its importance increases during foetal thyreopathies and 
insufficient production of thyroid hormones by the foetus. Total production of thyroid 
hormones in gravidity increases by about 25 – 30% (Karásek, 2007). A tendency to 
subclinical hypothyreosis during pregnancy was observed in a significant proportion of 
women with normal free thyroxin and TSH levels. The impact of subclinical or even 
manifest hypothyreosis during pregnancy on recurrent miscarriages is evidenced by the 
time when miscarriages occur - usually during the first trimester when the foetus is 
completely dependent on its mother’s production of thyroid hormones (Poppe, 2003). 
2.2.2.2 Diagnosis of hypothyreosis 
Primary hypothyreosis by increased TSH levels and reduced free T3 and free T4 levels, 
central hypothyreosis is then characterized by decreased or normal (i.e. not adequately 
increased) TSH levels (Brunová, 2008). 
2.2.2.3 Treatment of hypothyreosis 
Treatment of hypothyreosis is initiated with small doses of 25 μg/day and sometimes just 12.5 
μg/day of thyroxin. The dose is increased every 7 – 14 days to the expected maintenance dose. 
The dose is reduced again if the patient poorly tolerates the treatment, i.e. suffers from 
palpitations, angina pectoris or has signs of heart failure. The demand for thyroid hormone 
secretion increases during pregnancy and thus thyroxin dose in mothers previously treated for 
hypothyreosis should be increased during pregnancy by 30% or even 50% (Brunová, 2008). 
2.2.3 Diabetes mellitus 
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycaemia 
developing as a result of insulin secretion disorder or as an effect of insulin or a combination 
of these factors. The main symptom is hyperglycaemia. From biochemical perspective, 
diabetes influences metabolism of carbohydrates, lipids and proteins. Clinically, it is 
responsible for the development of microvascular and macrovascular complications 
associated with organ specific degenerative processes and leading to neuropathic 
complications (diabetic ketoacidosis, cardiovascular complications, diabetic retinopathy, 
neuropathy, nephropathy), (Ďuriš, 2001). 
Classification of diabetes mellitus: 
a. Diabetes mellitus 
1. Type 1 diabetes mellitus - insulin-dependent 
2. Type 2 diabetes mellitus - non-insulin-dependent 
3. Malnutrition-related diabetes mellitus 
4. Other specific types (secondary) of diabetes mellitus – hyperglycaemia associated 
with another cause (e.g. pancreatic disease, endocrinopathy). 
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b. Impaired glucose tolerance 
c. Gestational diabetes mellitus 
2.2.3.1 Pathophysiology of diabetes mellitus 
Diabetic female patients are more frequently diagnosed with an ovulatory disorder 
leading to infertility. A comparison of hormonal profile of diabetic patients suffering from 
amenorrhoea and women with regular menses suggests different pathophysiological 
mechanisms, specifically the presence of hyperandrogenism. The effects of 
hyperinsulinaemia are particularly important. Hyperinsulinaemia stimulates 
androgenesis in the ovaries. This stimulation is via IGF receptors found in the ovaries 
present in sufficient amount. This is either a traditional example of the linkage between 
insulin and steroidogenesis or a hyperreactivity of ovarian receptors for a different reason 
(Svačina, 1997). According to this theory, changes to pituitary hormones might be 
secondary, determined by higher level of androgens. Defect of serine phosphorylation 
with a common manifestation on peripheral insulin receptors, ovaries and adrenal glands 
represents another significant theory. A slight increase in total testosterone and 
androstendione levels occur despite concurrent increase in catabolism of androgens. 
Under normal circumstances, around 66% of the circulating testosterone is bound to the 
sex-hormone-binding globulin (SHBG). When fasting (e.g. anorexia), SHBG concentration 
increases. On the contrary, SHBG level decreases with increasing BMI, mainly in android 
obesity and polycystic ovary syndrome (particularly if associated with obesity) and in 
association with diabetes mellitus; this further increases android hormone concentrations. 
Hyperinsulinism that is associated with this disease, is one of the possible explanations. 
Experimental in vitro studies show that insulin has an inhibitory effect on SHBG synthesis 
in the liver (Cogswel, 2001). 
Hyperinsulinaemia is diagnosed in as many as 27% of women with a history of habitual 
abortion (Carrington, 2005) Hyperinsulinaemia influences endometrial functions by 
reducing the levels of the two main endometrial hormones, glycodelin and IGFBP (insulin-
like growth factor binding protein). Hyperinsulinaemia is diagnosed in 40–50% of women 
with the polycystic ovary syndrome (Kauffman, 2003). 
Spontaneous abortion is seen more often in women with decompensated diabetes mellitus 
(DM) during early pregnancy. It is more frequent in poorly compensated type 1 DM 
patients, although it is sometimes diagnosed in patients with type 2 DM that had not been 
diagnosed prior to their pregnancy. Pregnancy is considered a diabetogenic state and the 
onset of gestational diabetes mellitus is associated with an increased insulin resistance 
(Hájek, 2004).  
Decompensated type 1 diabetic females suffer more frequently from spontaneous abortions 
(even repeatedly), particularly as a consequence of higher incidence of diabetic 
embryopathy DE (2-3x more frequent in diabetics in comparison to healthy population). 
Diabetic embryopathy is a congenital developmental defect or a malformation of the foetus 
not compatible with life. Etiopathogenesis of DE has not been elucidated yet. Clinical and 
experimental knowledge confirm that hyperglycaemia is the main metabolic teratogen. 
Direct link between HbA1c level at the beginning of pregnancy and the incidence of diabetic 
embryopathy has been confirmed (Ďuriš, 2001). 
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2.2.3.2 Diagnosis of diabetes mellitus 
Diagnosis of diabetes mellitus is made from patient’s urine glucose levels and blood testing 
with oral Glucose Tolerance Testing (oGTT). Prior to conception, current metabolic 
compensation – glycaemic profile, glycosylated haemoglobin (HbA1C) and diabetic 
complications assessment – is reviewed. Pregnancy is not recommended in women with 
severe diabetic organ complications (Hájek, 2004) 
2.2.3.3 Treatment of diabetes mellitus 
Treatment should focus on supplementing or inhibiting the effects of the relevant hormones 
and careful diabetes mellitus control (dietary regimen, insulinotherapy). 
Classification of DM therapies: 
1. Non-pharmacological therapy 
 Patient education 
 Diet 
 Physical activity 
2. Pharmacological treatment 
 Insulin (in insulin-dependent type 1 DM and always during pregnancy with any 
type of diabetes) 
 Oral antidiabetics (non-insulin dependent type 2 DM) 
Treatment should be comprehensive, managed by an experienced diabetologist (Ďuriš, 
2001). Prescribing metformin, an insulin sensitizer, in women with PCOS represents 
therapeutic application of an agent with promising effects in the area of anovulation sterility 
and dysfertility (Višňová, 2003). 
2.2.4 Hyperprolactinaemia 
Prolactin is a polypeptide hormone synthesised by lactotropic cells of the anterior pituitary. 
The main effect of this hormone is ensuring adequate postpartum lactation. In collaboration 
with other hormones, prolactin influences the growth of mammary glands during pregnancy. 
Prolactin levels in women who do not breast feed decline quickly within two weeks after birth 
and ovulation is likely to restart within 10 weeks. Hyperprolactinaemia is a disease with a 
pathological increase in prolactin levels out of postpartum period (Ďuriš, 2001). 
2.2.4.1 Pathophysiology of hyperprolactinaemia 
Excessive prolactin levels reduce the effects of hypothalamic GnRH and thus normal pulsate 
secretion of luteinizing hormone and follicle-stimulating hormone. Elevated prolactin levels 
also have a negative effect on luteinizing hormone increase in the middle of a menstrual 
cycle (peak LH). Basal levels of gonadotropins are within the norm. Lack of pulsate 
gonadotropin secretion leads to the functional hypogonadism with anovulation. 
Anovulation cycles are clinically manifested as oligomenorrhoea or amenorrhoea with 
subsequent reduction in fertility. The clinical picture typically also includes galactorrhoea, 
symptoms of estrogen insufficiency (reduced vaginal secretion, osteoporosis), mood swings 
and hirsutism. Hyperprolactinaemia is found in women with chronic renal insufficiency, 
with liver cirrhosis and those using certain drugs (psychotropics, antiemetics, 
antihypertensives, H1 and H2 receptor antagonists). It is found in patients with 
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hypothalamic disease (cranial and nasopharyngeal irradiation), pituitary disease (tumours – 
prolactinoma, metastases, meningioma), with primary hypothyreosis or it may be idiopathic 
(Ďuriš, 2001). 
2.2.4.2 Diagnosis of hyperprolactinaemia 
The diagnosis of hyperprolactinaemia is made from rigorous medical history, detailed 
clinical assessment and blood prolactin levels. Prolactin levels above 16 ng/mL are 
considered as hyperprolactinaemia. Levels exceeding 200 ng/mL suggest prolactinoma, 200 
- 500 ng/mL is pathognomonic for prolactinoma and the levels exceeding 1000 ng/mL 
evidence an invasive tumour expanding to sinus cavernosum. Levels below 100 ng/mL are 
usually not a symptom of a pituitary tumour (Ďuriš, 2001). 
2.2.4.3 Treatment of hyperprolactinaemia 
Treatment of hyperprolactinaemia is determined by the primary cause. Surgery, specifically 
the transsphenoidal hypophysectomy (transcranial approach is required when large 
macroprolactinomas are treated), is the method of choice for diagnosed microprolactinomas 
and macroprolactinomas. Radiation therapy is a complementary method in patients with 
incurable microprolactinomas. Pharmacological treatment is used in patients with 
hyperprolactinaemia caused by hypothalamo-pituitary dysfunction or in those with 
idiopathic hyperprolactinaemia. Pharmacological agents used include dopamine agonists 
that normalize prolactin secretion in about 85 – 90% of patients and reduce the tumour in 
about 50%. The most frequently used agents include ergoline derivatives bromocryptine, 
lisuride and terguride (Ďuriš, 2001). 
3. Conclusion 
A comprehensive and interdisciplinary approach is required to diagnose the causes of 
habitual miscarriage in a woman. The use of simple and widely available assessment 
methods in the basic differential diagnosis algorithm is preferred. If these do not provide a 
clear identification of aetiology of infertility, it is suitable to use more specific and 
technically demanding techniques. Adequate differential diagnosis enables determination of 
likely aetiology and a use of an appropriately targeted therapy.  
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